VMD:NSD-Viemed Healthcare, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 5.51

Change

0.00 (0.00)%

Market Cap

USD 0.22B

Volume

0.01M

Average Target Price

N/A
Average Analyst Rating

N/A

STA Verdict

Verdict

About

Viemed Healthcare, Inc., through its subsidiaries, provides in-home health care solutions in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators, positive airway pressure machines, and oxygen units, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing to determine the existence of sleep apnea at home. In addition, the company leases equipment, including non-invasive ventilators, BiPaP and CPaP devices, percussion vests, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy, education, and counseling to patients in their homes using technology. The company is headquartered in Lafayette, Louisiana.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-01-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

N/A

USD22.12B 53.89 37.97
PODD Insulet Corporation

N/A

USD11.67B 731.63 143.82
BRKR Bruker Corporation

N/A

USD8.26B 40.94 23.25
ABMD Abiomed, Inc

N/A

USD8.19B 37.85 29.26
IART Integra LifeSciences Holdings ..

N/A

USD5.08B 86.20 17.65
SDC SmileDirectClub, Inc

N/A

USD5.07B N/A -1.65
NUVA NuVasive, Inc

N/A

USD4.07B 86.87 19.19
TNDM Tandem Diabetes Care, Inc

N/A

USD4.05B N/A -315.77
WMGI Wright Medical Group N.V

N/A

USD3.82B N/A 46.35
LIVN LivaNova PLC

N/A

USD3.55B 77.40 35.94

ETFs Containing VMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.13% 10% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.13% 10% F 6% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.22B 50% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.80 72% C- 45% F
Price/Book Ratio 4.97 46% F 26% F
Price / Cash Flow Ratio 9.71 32% F 38% F
EV/EBITDA 15.70 25% F 21% F
Management Effectiveness  
Return on Equity 26.14% 94% A 93% A
Return on Invested Capital 36.37% 89% B+ 94% A
Return on Assets 9.88% 93% A 94% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.65 51% F 39% F
Short Percent N/A N/A N/A N/A N/A
Beta -0.53 92% A- 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.